WO2011081488A2 - 밀겨 추출물 또는 이로부터 분리한 유효물질을 이용한 비만 개선제 조성물 - Google Patents
밀겨 추출물 또는 이로부터 분리한 유효물질을 이용한 비만 개선제 조성물 Download PDFInfo
- Publication number
- WO2011081488A2 WO2011081488A2 PCT/KR2010/009592 KR2010009592W WO2011081488A2 WO 2011081488 A2 WO2011081488 A2 WO 2011081488A2 KR 2010009592 W KR2010009592 W KR 2010009592W WO 2011081488 A2 WO2011081488 A2 WO 2011081488A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- extract
- obesity
- wheat bran
- compound
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/115—Cereal fibre products, e.g. bran, husk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Definitions
- the present invention relates to a composition for improving obesity using wheat bran extract or an active substance isolated therefrom.
- Obesity is an abnormal increase in fat tissue due to excessive accumulation of energy in the body due to an imbalance between energy intake and consumption (Clinical Endocrinology 28: 675-689, 1998; Clinical Obesity (eds. Kopelman PG, Stock MJ). 248-89 (Blackwell Science, Oxford 1998) Clinically, men are considered obese when their body fat is 25% or more than 30% of their body weight, and clinically they are BMI (Body Mass Index) Is more than 30.0 is defined as obesity.
- BMI Body Mass Index
- the causes of obesity include environmental and genetic factors such as high fat and high calorie diet, lack of exercise due to busy social environment, and endocrine disorders. Among them, about 50 to 70% of obesity is caused by environmental factors. It is known that the rest is due to genetic factors.
- Energy in the body is stored in the form of triglycerides in fat cells, and when the body's energy source is depleted, the stored fat is broken down into free fatty acids and glycerol to be used as an energy source, but excessive intake of energy leads to differentiation of fat cells. Promotes and increases the amount of fat stored in the body is a direct cause of obesity.
- Adipocytes are produced by differentiating from adipocytes, which include peroxisome proliferator-activated receptor ⁇ (PPAR ⁇ ), C / EBP family (CCAAT / enhancer binding proteins; C / EBR ⁇ , C / EBR ⁇ , and C / EBR ⁇ ).
- PPAR ⁇ peroxisome proliferator-activated receptor ⁇
- CCAAT / enhancer binding proteins C / EBR ⁇ , C / EBR ⁇ , and C / EBR ⁇
- Transcription factors called ADD1 / SREBP1c adipocyte determination differentiation factor 1 / (sterol regulatory element binding protein 1c) are known to play a central role ( Genes De 2000, 14 (11) 1293-1307).
- the present invention is also completed based on the fact that wheat bran extract or an active substance isolated therefrom inhibits the differentiation and adipocyte accumulation of adipocytes and also inhibits the expression of PPAR ⁇ , C / EBR ⁇ , and ADD1 / SREBP1c. .
- An object of the present invention is to disclose a composition for improving obesity using wheat bran extract or an active substance isolated therefrom.
- the bran extract tachioside (methoxy-hydroquinone-4- ⁇ -D-glucopyranoside) and 9,12,13-tree isolated from the bran extract
- the octadecyl sensan (9,12,13-trihydroxy-10 (E ) -octadecenoic acid)
- the preadipocytes accumulation suppressing the differentiation of adipocytes and the local promotion of differentiation by insulin -hydroxy -10 (E)
- PPAR ⁇ , C / EBR ⁇ and ADD1 / SREBP1c which are inhibitors and are centrally involved in the differentiation of adipocytes.
- Tachioxide in the compound is a substance that has been separated from sugarcane molasses, Berchemia racemosa , bamboo culm and the like [J. Agr. Food Chem. 31: 545-548 (1983); Phytochemistry 26: 2811-2814 (1987); Food Sci. Biotechnol. 17 (6): 1376 to 1378 (2008)], and the compound 9,12,13-trihydroxy-10 ( E ) -octadecenoic acid was isolated from licorice, Colocasia antiquorum and the like. Bar material [Izv Akad Nauk SSSR Biol. 6: 932-6 (1988); Phytochemistry 28: 2613-2615 (1989).
- the obesity improver composition of the present invention is characterized in that it comprises wheat bran extract, a compound of [Formula 1] and / or a compound of [Formula 2] separated therefrom as an active ingredient.
- the "wheat bran” means a by-product obtained in the process of milling wheat. These by-products are usually composed of the rind (seed shell) and the embryo, except for the endosperm, which is flour, or when the embryo is separated with the endosperm during milling of wheat. Wheat bran can contain small amounts of embryos and embryos. The bran powder obtained by crushing wheat bran may be further subdivided into bran, powder, shank, isocracker, etc. according to the particle size, and in the present specification, "bran bran” includes the bran, powder, shank, isocracker, etc. derived from the wheat bran powder. I mean.
- the "extract” means lower alcohols having 1 to 4 carbon atoms such as water, methanol, ethanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N- Obtained by fractionating the crude extract obtained by using dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof and one or more of the above-listed solvents. Refers to the fraction.
- DMF dimethylformamide
- DMSO dimethyl sulfoxide
- 1,3-butylene glycol 1,3-butylene glycol
- propylene glycol or a mixed solvent thereof and one or more of the above-listed solvents.
- the extraction method may be applied in any manner, such as cooling, reflux, heating, ultrasonic radiation in consideration of the degree of extraction, the degree of preservation of the active ingredient.
- the crude extract is suspended in a specific solvent and mixed and fixed with a solvent having a different polarity.
- the crude extract is adsorbed onto a column filled with silica gel and the like, followed by a hydrophobic solvent, a hydrophilic solvent, or a mixture thereof. It is meant to include a fraction obtained by using a mixed solvent as a mobile phase.
- the meaning of the extract includes a concentrated liquid extract or solid extract in which the extraction solvent is removed in a manner such as freeze drying, vacuum drying, hot air drying, spray drying, and the like.
- it means an extract obtained using water, ethanol or a mixed solvent thereof.
- the term “obesity” refers to a state in which fat tissue is abnormally increased, whether it is caused by genetic factors or obesity due to environmental factors, and obesity according to the classification of body mass index (BMI is 30.0 Above) and overweight (if your BMI is 25-30).
- the "active ingredient” refers to a component that can exhibit the activity alone or in combination with a carrier having no activity in itself.
- improving obesity is meant to include the reduction of body fat and / or weight loss, including the prevention of obesity, the treatment of obesity.
- the obesity improver composition of the present invention may include any effective amount (effective amount) according to the use, formulation, formulation purpose, etc., as long as the effective ingredient can exhibit the activity to improve obesity, the usual effective amount is based on the total weight of the composition When determined to be in the range of 0.001% to 99.990% by weight.
- the "effective amount” refers to the amount of the active ingredient that can induce the effect of improving obesity. Such effective amounts can be determined experimentally within the range of ordinary skill in the art.
- compositions of the invention are mammals and humans, in particular humans.
- the present invention relates to a diet composition
- a diet composition comprising wheat bran extract, the compound of [Formula 1] and / or the compound of [Formula 2] isolated from it as an active ingredient.
- die is defined as a condition in which a weight condition is not obese or overweight, but for which a reduction in weight / body fat is desirable or necessary for cosmetic or health purposes.
- the composition for a diet of the present invention will be manufactured and used for use for normal beauty or health purposes.
- the above-mentioned bar is effective as it relates to the obesity improving composition of the present invention.
- the present invention relates to an insulin resistance improving composition
- an insulin resistance improving composition comprising wheat bran extract, a compound of the formula [1] and / or a compound of the formula [2] separated from it.
- Obesity is one of several causes of insulin resistance. In some cases, high resistance to obesity does not develop insulin resistance, but insulin resistance and obesity are closely related, and in general, the more severe the obesity (visceral obesity) is known to increase the insulin resistance.
- adipocytokines there are those that promote insulin sensitivity and cause insulin resistance.
- the former are adiponectin, leptin, and AMPK (AMP-dependent protein kinase), and the latter is TNF.
- AMPK AMP-dependent protein kinase
- Fatty acid synthase Fas
- adiocytes adipocyte fatty acid-binding protein 2
- Fas is initially expressed in the differentiation of adipocytes (J. Biol. Chem., 255: 4745-4750 (1980)) and palmitate from acetyl-CoA and malonyl-CoA It is an enzyme that produces (palmitate), and Fas stores excess energy in the form of triglycerides to cause obesity, while the triglycerides produced by it, palmitate, are reported to destroy the pancreatic ⁇ cells causing insulin resistance. (Proc. Natl. Acad. Sci. 95: 2498-2502 (1998)), aP2 is a powerful target for the development of insulin-resistant therapies due to the low incidence of insulin resistance in mice lacking the gene and the decrease of aP2 inhibitors in insulin resistance. Proposed as a protein (Nature 447: 959-965 (2007)).
- the present inventors consider the possibility of using the compound of [Formula 1] and the compound of [Formula 2], which are effective ingredients of the obesity improving agent composition of the present invention, as an insulin resistance improving agent, thereby causing insulin resistance in the adipocytes treated with the compounds.
- an insulin resistance improving agent thereby causing insulin resistance in the adipocytes treated with the compounds.
- the compounds of [Formula 1] and [Formula 2] can be usefully used as an anti-obesity enhancer as well as an obesity improver.
- insulin resistance refers to a state in which an individual such as a cell, an organ, or a human body needs more than a usual amount of insulin for normal metabolic activity, that is, an insufficiency state of insulin in which insulin's action force is reduced.
- Insulin-independent diabetes or type 2 diabetes Diabetes is an insulin-dependent diabetes mellitus (type 1 diabetes) that requires insulin for its treatment as a result of the destruction of ⁇ -cells in the pancreas, and insulin-independent diabetes mellitus, which does not require insulin for its treatment.
- Type 2 diabetes insulin resistance, insulin independent diabetes and type 2 diabetes are taken in the same sense in the art.
- the meaning of wheat bran extract, its effective amount, and the like, as described above with respect to the obesity improver composition of the present invention is effective as it is.
- composition of this invention can be grasped
- the food composition of the present invention may be prepared as a dietary supplement, a special nutritional supplement, a functional beverage, and the like.
- the food composition of the present invention may include sweeteners, flavoring agents, bioactive ingredients, minerals, etc. in addition to the active ingredients.
- Sweeteners may be used in amounts that give the food a suitable sweet taste, and may be natural or synthetic.
- a natural sweetener is used.
- sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose and maltose.
- Flavoring agents can be used to enhance the taste or aroma, both natural and synthetic. It is the case of using a natural thing preferably.
- the natural flavor may be obtained from apples, lemons, citrus fruits, grapes, strawberries, peaches, and the like, or may be obtained from green tea leaves, round leaves, date leaves, cinnamon, chrysanthemum leaves, jasmine and the like.
- ginseng red ginseng
- bamboo shoots aloe vera, ginkgo and the like
- Natural flavors can be liquid concentrates or solid extracts.
- synthetic flavoring agents may be used, and synthetic flavoring agents may include esters, alcohols, aldehydes, terpenes, and the like.
- catechins such as catechin, epicatechin, gallocatechin, epigallocatechin, vitamins such as retinol, ascorbic acid, tocopherol, calciferol, thiamine, riboflavin, and the like can be used.
- mineral calcium, magnesium, chromium, cobalt, copper, fluoride, germanium, iodine, iron, lithium, magnesium, manganese, molybdenum, phosphorus, potassium, selenium, silicon, sodium, sulfur, vanadium, zinc and the like can be used.
- the food composition of the present invention may contain a preservative, an emulsifier, an acidulant, a thickener, and the like, in addition to the sweetener.
- Such preservatives, emulsifiers and the like are preferably added and used in very small amounts as long as the use to which they are added can be achieved.
- trace amount is meant numerically expressed in the range of 0.0005% to about 0.5% by weight based on the total weight of the food composition.
- preservatives examples include sodium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, EDTA (ethylenediaminetetraacetic acid), and the like.
- Emulsifiers that can be used include acacia gum, carboxymethylcellulose, xanthan gum, pectin and the like.
- acidulants examples include lead acid, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid, and the like. Such acidulant may be added so that the food composition is at an appropriate acidity for the purpose of inhibiting the growth of microorganisms in addition to the purpose of enhancing taste.
- Thickeners that can be used include suspending implements, sedimenters, gel formers, swelling agents and the like.
- the food composition of the present invention is already known to have an activity for improving obesity or improving liver function in order to improve flavor and palatability, to enhance or enhance its functionality, or to add other functionalities (such as fatty liver improving activity and hangover relieving activity).
- It may include powders or extracts derived from natural products of, ointment powder or extracts, bean sprouts powder or extracts, shellfish powder or extracts, oyster powder or extracts, parsley powder or extracts, radish juice or extracts, cucumber juice or extracts, leek Juice or extract, spinach juice or extract, lotus root juice or extract, sesame juice or extract, pine needle juice or extract, ginseng juice or extract, birch powder or extract, licorice powder or extract, brownish powder or extract, brown root powder or extract, Sine powder or extract, gourd powder or extract, ginger powder Silver extract, jujube powder or extract, phosphorus powder or extract, spermatozoon powder or extract, hydrophobic powder or extract, white extract powder or extract, spirit powder or extract
- composition of the present invention can be used as a pharmaceutical composition in a specific embodiment.
- compositions of the present invention include oral formulations (tablets, suspensions, granules, emulsions, capsules, syrups, etc.), parenteral formulations (sterile injectable aqueous or Oily suspensions), topical formulations (solutions, creams, ointments, gels, lotions, patches) and the like.
- pharmaceutically acceptable means that the subject of application (prescription) does not have more toxicity (adequately low toxicity) to which the subject of application (prescription) is adaptable without inhibiting the activity of the active ingredient.
- Examples of pharmaceutically acceptable carriers include lactose, glucose, sucrose, starch (such as corn starch, potato starch, etc.), cellulose, derivatives thereof (such as sodium carboxymethyl cellulose, ethylcellulose, etc.) malt, gelatin, talc, solids Lubricants (e.g. stearic acid, magnesium stearate, etc.), calcium sulfate, vegetable oils (e.g. peanut oil, cottonseed oil, sesame oil, olive oil, etc.), polyols (e.g. propylene glycol, glycerin, etc.), alginic acid, emulsifiers (e.g. TWEENS), wetting agents (e.g.
- Sodium lauryl sulfate Sodium lauryl sulfate
- colorants such as sodium lauryl sulfate
- flavoring agents such as sodium lauryl sulfate
- tableting agents such as sodium lauryl sulfate
- stabilizers such as sodium lauryl sulfate
- antioxidants such as sodium lauryl sulfate
- preservatives water, saline, phosphate buffer solutions and the like.
- Excipients may be selected and used according to the formulation of the pharmaceutical composition of the present invention, for example, when the pharmaceutical composition of the present invention is prepared with an aqueous suspending agent, suitable excipients are sodium carboxymethyl cellulose, methyl cellulose, hydropropylmethylcellulose And suspending agents and dispersing agents such as sodium alginate and polyvinylpyrrolidone. Suitable excipients when prepared as injections include Ringer's solution, isotonic sodium chloride, and the like.
- the pharmaceutical composition of the present invention may be administered orally or parenterally and in some cases may be administered topically.
- the daily dosage of the pharmaceutical composition of the present invention is usually 0.001 ⁇ 150 mg / kg body weight range, it can be administered once or divided into several times. However, since the dosage of the pharmaceutical composition of the present invention is determined in view of various related factors such as the route of administration, the age, sex, weight of the patient, and the severity of the patient, the dosage may limit the scope of the present invention in any aspect. It should not be understood as.
- the present invention can provide an obesity improving composition.
- the present invention can provide an insulin resistance improving agent composition.
- Obesity improver composition and insulin improver composition of the present invention can be commercialized as a functional food, drugs and the like.
- 17 and 18 are results showing that the bran extract, the compound of [Formula 1] and the compound of [Formula 2] inhibit the expression of PPAR ⁇ and C / EBR ⁇ at the protein level in a concentration-dependent manner.
- Ethanol was added to wheat bran, a by-product of mill of Triticum aestivum L., and extracted by cold sedimentation three times for 24 hours.
- the filtrate was filtered and the filtrate was obtained using a vacuum concentrator.
- the extract was suspended in distilled water, and then the solvent was fractionated with CH 2 Cl 2 , and then the solvent was fractionated with butanol for the water layer, butanol fraction layer (G36W) Got.
- the butanol fractionation layer (G36W) was then evaporated under reduced pressure to obtain a butanol extract.
- Diaion HP-20 column chromatography was performed on a water-methanol mobile phase (water, 20, 40, 60, 80, 100% methanol). And divided into six subfractions (G36W-18-1 ⁇ 6).
- FIG. 1 A schematic diagram of the separation process of Compounds 1 and 2 is shown in FIG. 1.
- the separated compound 1 was subjected to physicochemical and spectroscopic analysis.
- Compound 1 was assumed to be a glucose-coupled compound to methoxyhydroquinone, and the physical and chemical properties ( Food Sci. Biotechnol. , 17 (6), 1376-1378, Tachioside, an antioxidative phenolic glycoside from bamboo Species) was compared and compared to determine the tachioside (methoxy-hydroquinone-4- ⁇ -D-glucopyranoside) of [Formula 1].
- the separated compound 2 was subjected to physicochemical and spectroscopic analysis.
- 3T3-L1 a mouse precursor cell, was added with 10% BCS DMEM medium and cultured at 37 ° C. and 5% CO 2 .
- Preadipocytes induced adipocyte differentiation for 2 days with 10% FBS DMEM medium containing MDI (0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 1 uM dexamethasone, 1 ug / ml insulin). After hours, the cells were incubated for 2 days with 10% FBS DMEM containing 1 ug / ml insulin. It was then replaced with 10% FBS DMEM culture for 4 days every 2 days.
- MDI 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 1 uM dexamethasone, 1 ug / ml insulin
- adipocyte differentiation During the induction of adipocyte differentiation, the samples were treated by concentration in each culture, and the degree of adipocyte differentiation was observed on day 8, when the differentiation was completed. The degree of adipocyte differentiation was primarily confirmed by microscopy through Oil Red O staining, and the degree of adipocyte staining was measured at 510 nm absorbance.
- the wheat bran extract, and the compounds 1 and 2 isolated therefrom have a concentration-dependent proliferative cell proliferation inhibitory activity to adipocytes.
- Recombinant vector obtained by inserting PPAR ⁇ response element (PPRE) gene and PPAR ⁇ gene into pGL3-basic luciferase expression vector (Promega) and pRL-SV-40 plasmid (Promega) containing Renilla luciferase cDNA as HEK 293T cell. Co-transfection. Genes were expressed for one day and then treated with samples (Red-dog A & Red-dog B and Compounds 1 & 2) alone or with PPAR ⁇ -inducing substance 10uM troglitazone for 24 hours by concentration. The degree of transcriptional activity of was observed through luciferase expression intensity.
- PPRE PPAR ⁇ response element
- the expression level of / SREBP1c was confirmed by real-time PCR. After washing the differentiated 3T3-L1 cells with PBS twice for 8 days, cell pellets were collected and RNA was isolated by RNA prep kit (Qiagen). CDNA was synthesized using 1 ug of extracted RNA, and then real-time PCR was performed using SYBR green (Takara) and the primers in [Table 1], and the control gene was GAPDH.
- PCR composition was 5ul by diluting cDNA synthesized with 1ug of RNA to 1/50 with distilled water, and 0.5ul for 10 pmole primer, 10ul for 2X SYBR green, and 4ul for distilled water to adjust the total volum to 20ul.
- the initial degeneration was 95 °C 30 seconds
- the degeneration was 95 °C 5 seconds
- the annealing was 60 °C 15 seconds
- the extension reaction was 72 °C 10 seconds
- the melting curve started at 55 °C and 95 °C.
- the desired fluorescence value was detected by increasing 80 ° C by 0.5 ° C (quantitative fluorescence signal was used by Bio-Rad MyiQ program).
- 3T3-L1 cells were treated with samples (Red-dog A & Red-dog B and Compounds 1 & 2) every two days, and the cells were washed twice with PBS and RIPA buffer (50 mM Tris). Cells were lysed using -HCl, pH 8.0, 150mM sodium chloride, 1% NP-40, 0.5% sodium dexycholate, 0.1% sodium dodecyl sulfate, protease inhibitor). Protein was extracted and quantified by centrifugation at 13000 rpm for 30 minutes and electrophoresed using 8% SDS-PAGE gel. Electrophoretic proteins were transferred to the membrane and blocked with TBST containing 5% skim milk.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Gene name | Forward primer | Reverse primer |
GAPDH | GAGTCAACGGATTTGGTCGT(서열번호 1) | GACAAGCTTCCCGTTCTCAG(서열번호 2) |
PPARγ | CGCTGATGCACTGCCTATGA(서열번호 3) | AGAGGTCCACAGAGCTGATTCC(서열번호 4) |
C/EBPα | AGGTGCTGGAGTTGACCAGT(서열번호 5) | CAGCCTAGAGATCCAGCGAC(서열번호 6) |
ADD1/SREBP1c | CAAACTGCCCATCCACCGAC(서열번호 7) | TGCCTCCTCCACTGCCACAA(서열번호 8) |
Gene name | Forward primer | Reverse primer |
GAPDH | GAGTCAACGGATTTGGTCGT(서열번호 9) | GACAAGCTTCCCGTTCTCAG(서열번호 10) |
aP2 | CATGGCCAAGCCCAACAT(서열번호 11) | CGCCCAGTTTGAAGGAAATC(서열번호 12) |
Resistin | TCAACTCCCTGTTTCCAAATGC(서열번호 13) | TCTTCACGAATGTCCCACGA(서열번호 14) |
Fas | CTGAGATCCCAGCACTTCTTGA(서열번호 15) | GCCTCCGAAGCCAAATGAG(서열번호 16) |
Claims (12)
- 밀겨 추출물, 타치오시드(tachioside), 또는 9,12,13-트리하이드록시-10(E)-옥타데센산(9,12,13-trihydroxy-10(E)-octadecenoic acid)을 유효성분으로 포함하는 비만 개선제 조성물.
- 제1항에 있어서,상기 밀겨 추출물은 물, 에탄올 또는 이들의 혼합 용매로 추출하여 얻은 추출물인 것을 특징으로 하는 비만 개선제 조성물.
- 제1항에 있어서,상기 조성물은 식품 조성물인 것을 특징으로 하는 비만 개선제 조성물.
- 제1항에 있어서,상기 조성물은 약제학적 조성물인 것을 특징으로 하는 비만 개선제 조성물.
- 밀겨 추출물, 타치오시드(tachioside), 또는 9,12,13-트리하이드록시-10(E)-옥타데센산(9,12,13-trihydroxy-10(E)-octadecenoic acid)을 유효성분으로 포함하는 다이어트용 조성물.
- 제5항에 있어서,상기 밀겨 추출물은 물, 에탄올 또는 이들의 혼합 용매로 추출하여 얻은 추출물인 것을 특징으로 하는 비만 개선제 조성물.
- 제5항에 있어서,상기 조성물은 식품 조성물인 것을 특징으로 하는 다이어트용 조성물.
- 제5항에 있어서,상기 조성물은 약제학적 조성물인 것을 특징으로 하는 다이어트용 조성물.
- 밀겨 추출물, 타치오시드(tachioside), 또는 9,12,13-트리하이드록시-10(E)-옥타데센산(9,12,13-trihydroxy-10(E)-octadecenoic acid)을 유효성분으로 포함하는 인슐린 저항성 개선제 조성물.
- 제9항에 있어서,상기 상기 밀겨 추출물은 물, 에탄올 또는 이들의 혼합 용매로 추출하여 얻은 추출물인 것을 특징으로 하는 비만 개선제 조성물.
- 제9항에 있어서,상기 조성물은 식품 조성물인 것을 특징으로 하는 인슐린 저항성 개선제 조성물.
- 제9항에 있어서,상기 조성물은 약제학적 조성물인 것을 특징으로 하는 인슐린 저항성 개선제 조성물.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/520,161 US20130102554A1 (en) | 2009-12-30 | 2010-12-30 | Composition for treatment of obesity using wheat bran extract or active ingredient isolated therefrom |
CN201080060141.2A CN102686227B (zh) | 2009-12-30 | 2010-12-30 | 一种使用麦麸提取物或由其分离得到的活性成分治疗肥胖症的组合物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090134278A KR101082460B1 (ko) | 2009-12-30 | 2009-12-30 | 밀겨 추출물을 이용한 비만 개선제 조성물 |
KR10-2009-0134278 | 2009-12-30 | ||
KR10-2010-0077286 | 2010-08-11 | ||
KR1020100077286A KR101231583B1 (ko) | 2010-08-11 | 2010-08-11 | 밀겨 추출물로부터 분리한 유효물질을 이용한 비만 개선제 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011081488A2 true WO2011081488A2 (ko) | 2011-07-07 |
WO2011081488A3 WO2011081488A3 (ko) | 2011-12-01 |
Family
ID=44227070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/009592 WO2011081488A2 (ko) | 2009-12-30 | 2010-12-30 | 밀겨 추출물 또는 이로부터 분리한 유효물질을 이용한 비만 개선제 조성물 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20130102554A1 (ko) |
CN (1) | CN102686227B (ko) |
WO (1) | WO2011081488A2 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140295011A1 (en) * | 2011-10-27 | 2014-10-02 | Genematrix Inc. | Composition Containing Triticum Aestivum Lamarck Leaf Extract or Fraction Thereof as Active Ingredient |
WO2017111429A1 (ko) * | 2015-12-21 | 2017-06-29 | 동아제약 주식회사 | 들쭉 추출물을 유효성분으로 포함하는 안구건조증 치료용 조성물 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103005282A (zh) * | 2013-01-05 | 2013-04-03 | 江苏大学 | 一种具有降糖作用的麦麸提取物保健食品及其制备方法 |
WO2015071413A1 (en) * | 2013-11-15 | 2015-05-21 | Universitat Autonoma De Barcelona | Wheat bran soluble extract as anti-biofilm agent |
CN109568563B (zh) * | 2019-02-02 | 2023-01-17 | 北京胜泰生物医药科技有限公司 | 一种沸石负载天然提取物的组合物及其制备方法 |
WO2022246313A1 (en) * | 2021-05-21 | 2022-11-24 | The Coca-Cola Company | Sweetness enhancement and taste modulation with digupigan a analogs |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5841824A (ja) * | 1981-09-07 | 1983-03-11 | Nippon Shokuhin Kako Kk | 血清コレステロ−ル上昇抑制物質 |
JPH03145424A (ja) * | 1989-10-31 | 1991-06-20 | Manda Hakko Kk | 糖類吸収抑制剤 |
US5260283A (en) * | 1992-05-19 | 1993-11-09 | American Health Foundation | Method for altering excretion of estrogens or lipids in mammals |
JP2007182395A (ja) * | 2006-01-05 | 2007-07-19 | Nisshin Pharma Inc | 脂肪低下組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0678367B2 (ja) * | 1990-05-15 | 1994-10-05 | 呉羽化学工業株式会社 | 食物繊維、その製造法及びその食物繊維を含有する生理活性剤 |
CA2420601A1 (en) * | 2000-08-31 | 2003-02-26 | The Kitasato Institute | Vaccine preparation containing fatty acid as component |
-
2010
- 2010-12-30 CN CN201080060141.2A patent/CN102686227B/zh active Active
- 2010-12-30 WO PCT/KR2010/009592 patent/WO2011081488A2/ko active Application Filing
- 2010-12-30 US US13/520,161 patent/US20130102554A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5841824A (ja) * | 1981-09-07 | 1983-03-11 | Nippon Shokuhin Kako Kk | 血清コレステロ−ル上昇抑制物質 |
JPH03145424A (ja) * | 1989-10-31 | 1991-06-20 | Manda Hakko Kk | 糖類吸収抑制剤 |
US5260283A (en) * | 1992-05-19 | 1993-11-09 | American Health Foundation | Method for altering excretion of estrogens or lipids in mammals |
JP2007182395A (ja) * | 2006-01-05 | 2007-07-19 | Nisshin Pharma Inc | 脂肪低下組成物 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140295011A1 (en) * | 2011-10-27 | 2014-10-02 | Genematrix Inc. | Composition Containing Triticum Aestivum Lamarck Leaf Extract or Fraction Thereof as Active Ingredient |
WO2017111429A1 (ko) * | 2015-12-21 | 2017-06-29 | 동아제약 주식회사 | 들쭉 추출물을 유효성분으로 포함하는 안구건조증 치료용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
CN102686227A (zh) | 2012-09-19 |
CN102686227B (zh) | 2014-12-03 |
US20130102554A1 (en) | 2013-04-25 |
WO2011081488A3 (ko) | 2011-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011007943A1 (ko) | 다물린 에이 및 다물린 비 함량이 증가된 신규 돌외추출물의 제조방법 및 이를 이용한 대사질환 치료용 약학 조성물 | |
WO2011081488A2 (ko) | 밀겨 추출물 또는 이로부터 분리한 유효물질을 이용한 비만 개선제 조성물 | |
AU2012266308B2 (en) | Composition comprising cashew apple extract | |
KR20070080329A (ko) | 어성초 추출물을 함유한 암 예방 및 치료용 조성물 | |
KR101110061B1 (ko) | 가시파래 추출물과 그것의 항염증제로서의 용도 | |
JP5813576B2 (ja) | サーチュイン1(sirt1)遺伝子活性化剤 | |
WO2019050123A1 (ko) | 가자나무열매추출물 및 암라추출물을 포함하는 비만 또는 고지혈증 개선용 식품 조성물 | |
KR20140114801A (ko) | 제주조릿대 잎 추출물 또는 그로부터 분리된 파라-쿠마르산을 이용한 비만 및 지방간 개선제 조성물 | |
KR20140100117A (ko) | 오리나무 추출물 또는 그로부터 분리된 화합물을 포함하는 지방분화 억제용 조성물 | |
JP2022535353A (ja) | インディアングーズベリー抽出物と大麦若葉抽出物との複合物(ib複合物)を有効成分として含む肥満及び/または糖尿を伴うメタボリックシンドロームの予防、改善治療用組成物 | |
WO2011081489A2 (ko) | 밀겨 추출물 또는 이로부터 분리한 유효물질을 이용한 알러지성 질환의 개선제 조성물 | |
KR101231583B1 (ko) | 밀겨 추출물로부터 분리한 유효물질을 이용한 비만 개선제 조성물 | |
KR101119167B1 (ko) | 체지방 억제에 유용한 약용식물 추출물을 포함하는 항 비만조성물 | |
KR101613685B1 (ko) | 푸코산틴 유도체를 이용한 항비만용 조성물 | |
KR101082460B1 (ko) | 밀겨 추출물을 이용한 비만 개선제 조성물 | |
KR101385191B1 (ko) | 치커리 추출물의 근육 손상 예방, 치료 또는 개선을 위한 용도 | |
US20040044067A1 (en) | Toralactone and its derivation and the use of decreasing blood-fat and losing weight | |
KR101601843B1 (ko) | 사링고스테롤을 포함하는 항비만용 조성물 | |
Sun et al. | NF-${\kappa} B $ Inhibitory Activities of Phenolic and Lignan Components from the Stems of Acanthopanax divaricatus var. albeofructus | |
KR20140039809A (ko) | 소야사포닌 Aa를 포함하는 비만 또는 지질 관련 대사성 질환 예방 또는 치료용 조성물 | |
JP2013177355A (ja) | メタボリックシンドロームを予防及び治療するための有機体由来の天然成分及び抽出物 | |
KR101473748B1 (ko) | 문주란 추출물을 이용한 항비만 조성물 및 항고지혈증 조성물 | |
WO2018038313A1 (ko) | 신규한 디노익산 화합물 및 이를 포함하는 골 질환의 예방 또는 치료용 약학적 조성물 | |
KR20190061787A (ko) | 로열젤리를 포함하는 비만과 고지혈증의 개선, 예방 또는 치료를 위한 조성물 | |
WO2015093634A1 (ko) | 치커리 추출물의 근육 손상 예방, 치료 또는 개선을 위한 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080060141.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10841320 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13520161 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10841320 Country of ref document: EP Kind code of ref document: A2 |